Objective: Type II endoleaks (T2EL) are the most common cause of reintervention after endovascular aneurysm repair (EVAR). While most resolve spontaneously, the long-term implications of T2EL remain elusive. We aim to evaluate the impact of persistent and late T2EL on clinical outcomes after EVAR.
Methods: Single institution retrospective review of patients who underwent EVAR for degenerative infrarenal abdominal aortic aneurysm between January 2010 and June 2022 with no Type I (T1EL) or III (T3EL) endoleak seen at EVAR completion. Patients were categorized based on T2EL status. Group 1 included patients with never detected or transient T2EL (detected at EVAR completion but not after). Group 2 encompassed persistent T2EL (seen at EVAR completion and again during follow-up) and late T2EL (detected for the first time at any point during follow-up). Time-to-event analysis was conducted using a time-dependent approach to T2EL status. Primary outcomes included freedom from sac enlargement (SE), aneurysm-related reinterventions, and overall survival.
Results: 803 patients met inclusion criteria. Group 1 included 418 patients (52%), of which 85% had no T2EL and 15% had transient T2EL. Group 2 had 385 patients; 23% had persistent T2EL, and 77% developed a new T2EL. Patients in group 1 had a higher prevalence of smoking (88% vs. 83%; p<0.001), COPD (33% vs. 25%; p=0.008), chronic kidney disease (13% vs. 8%; p=0.021) and a higher mean SVS score (7 vs. 6 points; p=0.049). No differences were found in aneurysm diameter or morphology. Mean follow-up was 5 years for the entire cohort. In Group 2, 58 patients (15%) underwent T2EL treatment, most commonly transarterial embolization. At 10 years after EVAR, Group 2 was associated with lower freedom from SE (p<0.001) and AAA-related reinterventions (p<0.001) and comparable overall survival (p=0.42). More T1EL were detected during follow-up in Group 2 (6 [1%] vs. 20 [5%]; p=0.004), with 15 (75%) of these detected at a median of 3 years after the T2EL. No difference between groups was observed in explant (0.7% vs. 2.1%; p=0.130) or aneurysm rupture (0.5% vs. 1.3%; p=0.269) rates.
Conclusion: One-half of patients treated with infrarenal EVAR developed persistent/late T2ELs, which are associated with a higher risk of sac enlargement and reinterventions. No difference in overall survival or aneurysm rupture risk was seen at 10 years, based on T2EL status or T2EL intervention. A conservative approach to T2EL may be appropriate for most patients with absent T1EL or T3EL.
Keywords: Abdominal aortic aneurysm; Endoleak embolization; Endovascular aneurysm repair; Endovascular stent grafting; Type II endoleak.
Copyright © 2024. Published by Elsevier Inc.